Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA6 | P23280 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | TPMT | P51580 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.62 |
| ▸ | PDE4A | P27815 | 3/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30575456 | 1.00 | CA12 (0.63) | CA12CA1CA2CA4CA6 | |
| SCHEMBL7389578 | 0.94 | PDE4B (0.60) | CA12CA1CA2CA4CA6 | |
| SCHEMBL15596058 | 0.94 | TSHR (0.66) | CA12CA1CA2CA4CA6 | |
| SCHEMBL29670247 | 0.94 | TSHR (0.66) | CA12CA1CA2CA4CA6 | |
| SCHEMBL12508471 | 0.93 | PDE4B (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL28034346 | 0.91 | PDE4B (0.53) | CA12CA1CA2CA4CA6 | |
| SCHEMBL20428527 | 0.91 | CA12 (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL7411191 | 0.89 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6940040 | 0.89 | TSHR (0.62) | CA12CA1CA2CA4CA6 | |
| SCHEMBL4269812 | 0.88 | PDE4B (0.62) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICALC., LTD. (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-110305072-B | Compounds with phosphodiesterase 4D and acid sphingomyelinase inhibitory activity and uses thereof | 中国药科大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-112812077-B | Benzamide compound, preparation method thereof, pharmaceutical composition and application | 中国科学院上海药物研究所 | 2023-08-22 | — | — | CN | disclosed |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| CN-112812077-A | Benzamide compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-05-18 | — | — | CN | disclosed |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-12 | — | — | US | disclosed |
| CN-105085429-B | Aromatic heterocyclic derivative and application thereof in medicines | 广东东阳光药业有限公司 | 2019-12-10 | — | — | CN | disclosed |
| CN-110305072-A | Compound and its application with phosphodiesterase 4 D and acid sphingomyelinase inhibitory activity | 中国药科大学 | 2019-10-08 | — | — | CN | disclosed |
| CN-105085428-B | Aromatic heterocyclic derivatives and its application on drug | 广东东阳光药业有限公司 | 2019-03-22 | — | — | CN | disclosed |
| US-6096768-A | ADMINISTERING A 3, 5, 6-SUBSTITUTED PHENYL COMPOUND FOR THE TREATMENT OF INFLAMMATION AND AUTOIMMUNE DISORDERS | RHONE-POULENC RORER LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| US-5935978-A | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | RHONE-POULENC RORER LIMITED (GB) | 1999-08-10 | — | — | US | disclosed |
| US-5840724-A | COMPOUNDS FOR TUMOR NECROSIS FACTOR OR ENZYME INHIBITORS OF PHOSPHODIESTERASES | RHONE-POULENC RORER LIMITED (GB) | 1998-11-24 | — | — | US | disclosed |
| EP-0741707-B1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE POULENC RORER LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| US-5698711-A | INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS | RHONE-POULENC RORER LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| US-5679696-A | FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1997-10-21 | — | — | US | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | CA12 1478/4885CA1 614/4885CA2 44/4885 |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE7B, PDE4B, PDE1B | CA12 1905/4885CA1 1395/4885CA2 270/4885 |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | CA12 1478/4885CA1 614/4885CA2 44/4885 |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | CA12 1721/4885CA1 673/4885CA2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.